USSOCOM BAA for Extramural Biomedical and Human Performance Research and Development

Executive Summary:

United States Special Operations Command (USSOCOM) is awarding $2,000,000 to $10,000,000 for projects across defined Research Areas of Interest (RAIs) to advance biomedical, human performance, and canine medicine relevant to Special Operations Forces. This BAA is open continuously through 31 July 2028; applicants must first submit a pre-proposal via eBRAP and, if invited, a full application (generally within 60 days of invitation).

How much funding would I receive?

  1. Typical project size: $2 Million to $10 Million

  2. Program capacity: “Anticipated total costs… will not exceed $20 Million annually” across all awards funded under this BAA.

What could I use the funding for?

A primary emphasis of the USSOCOM Biomedical, Human Performance, and Canine Research Program is to identify and develop techniques, knowledge products, and materiel (medical devices, drugs, and biologics) to support far-forward early intervention of life-threatening illnesses or injuries within an Irregular Warfare or asymmetric, multi-domain operational environment. Special Operations Forces (SOF) medical personnel place a premium on medical equipment that is small, lightweight, ruggedized, modular, multi-use, and designed for operation in extreme environments. The equipment must be simple to employ, require minimum maintenance, and have low power consumption. Drugs and biologics should optimally not require refrigeration or other special handling. All materiel solutions must be capable of commercialization. Research projects may apply existing scientific and technical knowledge for which concept and/or patient care efficacy have already been demonstrated to meet SOF requirements. The proposed research must be relevant to active-duty service members, veterans, military beneficiaries, and/or the American public. Relevant research must be responsive to the health care needs of the U.S. Armed Forces, family members of the U. S. Armed Forces, and U.S. Veterans.

Proposals must address a relevant health problem responsive to one of the Research Areas of Interest below (Clinical trials are normally not funded by this BAA):

Are there any additional benefits I would receive?

Beyond direct funding, participation under the USSOCOM Biomedical and Human Performance BAA offers significant strategic advantages:

Government Validation and Credibility:
Being selected for funding by USSOCOM demonstrates exceptional technical capability and mission relevance to U.S. Special Operations Forces. This validation enhances your organization’s credibility with DoD program managers, defense primes, and dual-use technology investors seeking field-proven innovation.

Enhanced Market Visibility and Notoriety:
Awardees often gain visibility through federal award announcements, DoD communications, and defense medical research forums—positioning your company as a recognized contributor to national security and elite force readiness.

Ecosystem Access and Collaboration Opportunities:
Projects funded under this BAA operate within the broader military biomedical and human performance ecosystem, connecting recipients with military laboratories, medical R&D commands, and operational units. This access frequently leads to additional collaboration, follow-on funding, and contracting opportunities.

Stronger Exit and Acquisition Potential:
Advancing your technology with nondilutive government support and demonstrating validation in demanding SOF environments can significantly increase company valuation and strategic attractiveness for acquisition or investment by defense, medical, and performance technology leaders.

What is the timeline to apply and when would I receive funding?

  • Open period: Continuously open through 31 July 2028.

  • Two-step submission: Pre-proposal via eBRAP; if invited, submit the full application (generally within 60 days).

  • Review & notice: Applicants should receive disposition within ~180 days of submission; awards may be made any time throughout the year and are contingent on funding and successful negotiations.

  • Regulatory lead times: Allow 2–3 months for DoD human-subjects review (OHRO/HRPO) and 1–2 months for animal research review (VRO), as applicable.

Where does this funding come from?

Funding is provided by the Department of Defense (USSOCOM) and administered by the U.S. Army Medical Research Acquisition Activity (USAMRAA); the program leverages CDMRP/eBRAP systems. Any funds received by USSOCOM appropriate to the BAA’s research areas may be used, up to a program total of $20M annually.

Who is eligible to apply?

Organizations only: national/international, for-profit, non-profit, public, and private. FFRDCs are not eligible for direct awards but may team under their sponsoring agreements. Eligible investigators are individuals employed by/affiliated with eligible organizations. No cost sharing is required.

What companies and projects are likely to win?

Winning projects consistently score high on USSOCOM’s evaluation factors, which include:

  • Technical Merit and Scientific Rigor: The proposed approach must be well-founded, methodologically sound, and clearly linked to measurable outcomes.

  • Innovation and Impact: Reviewers favor projects that introduce novel methods, materials, or technologies capable of significantly improving SOF medical or performance capabilities. Incremental improvements without clear operational relevance tend to score poorly.

  • SOF Relevance: Proposals must explicitly tie their work to unique SOF operational needs—such as portability, durability, limited logistics support, or extreme-environment applicability.

  • Feasible Study Design and Realistic Execution Plan: Reviewers expect achievable milestones, well-defined deliverables, and credible transition pathways for eventual use by operational forces or integration into DoD systems.

  • Qualified Team and Institutional Capability: Teams with demonstrated expertise in biomedical R&D, human performance, or defense health technology—and with access to appropriate facilities and regulatory infrastructure—are prioritized.

  • Appropriate and Realistic Budget: Budgets should align with the scope and complexity of work, typically falling between $2 million and $10 million total costs for projects up to five years in duration.

Companies that combine strong technical innovation, credible execution capability, and a direct line of sight to SOF mission impact are most likely to be selected for funding.

Are there any restrictions I should know about?

  • Project length: Up to 5 years.

  • Pre-proposal required; unsolicited full proposals without invitation are rejected.

  • Clinical trials are typically not associated with this BAA.

  • Human/animal research approvals required.

  • Administrative pitfalls leading to rejection/withdrawal include: missing/over-limit narratives, missing budget, inclusion of URLs in prohibited sections, and inconsistencies between pre-proposal and full application.

How long will it take me to prepare an application?

For a first-time applicant, preparing a competitive pre-proposal will likely take 120–200 hours in total.

How can BW&CO help?

Our team specializes in complex federal R&D proposals and can:

  • Triple your likelihood of success through proven strategy and insider-aligned proposal development

  • Reduce your time spent on the proposal by 50–80%, letting your team focus on technology and operations

  • Ensure you are targeting the best opportunity for your project and positioning your company for long-term growth.

How much would BW&CO Charge?

Our full service support is available for the pre-proposal for $7000. Full proposal quoted upon invitation.

Fractional support is $300 per hour.

For startups, we offer a discounted rate of $250 per hour to make top-tier grant consulting more accessible while maintaining the same level of strategic guidance and proposal quality.

Additional Resources

View the Funding Announcement: HT9425-23-S-SOC1 BROAD AGENCY ANNOUNCEMENT (BAA) for Extramural Biomedical and Human Performance Research and Development Department of Defense



Previous
Previous

Barracks Resilience Through Industrialized Construction (BR-IC)

Next
Next

NIH STTR RFA-DA-25-047: Seeking Products to Address Social Needs Impacting Substance Use Disorders (SUD)